Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 246

1.

Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C.

Bruno S, Battezzati PM, Bellati G, Manzin A, Maggioni M, Crosignani A, Borzio M, Solforosi L, Morabito A, Ideo G, Podda M.

J Hepatol. 2001 May;34(5):748-55.

PMID:
11434622
3.

Viral and host factors in the prediction of response to interferon-alpha therapy in chronic hepatitis C after long-term follow-up.

Knolle PA, Kremp S, Höhler T, Krummenauer F, Schirmacher P, Gerken G.

J Viral Hepat. 1998 Nov;5(6):399-406.

PMID:
9857349
4.

Long-term follow-up study of sustained biochemical responders with interferon therapy.

Shindo M, Hamada K, Oda Y, Okuno T.

Hepatology. 2001 May;33(5):1299-302.

PMID:
11343259
5.

Long-term course of interferon-treated chronic hepatitis C.

Cammà C, Di Marco V, Lo Iacono O, Almasio P, Giunta M, Fuschi P, Vaccaro A, Fabiano C, Magrin S, Di Stefano R, Bonura C, Pagliaro L, Craxì A.

J Hepatol. 1998 Apr;28(4):531-7.

PMID:
9566819
6.

Hepatitis G infection and therapeutic response to interferon in HCV-related chronic liver disease.

Pramoolsinsap C, Poovorawan Y, Sura T, Theamboonlers A, Busagorn N, Kurathong S.

Southeast Asian J Trop Med Public Health. 1998 Sep;29(3):480-90.

PMID:
10437943
7.

Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1,386-patient study from Taiwan.

Huang JF, Yu ML, Lee CM, Dai CY, Hou NJ, Hsieh MY, Wang JH, Lu SN, Sheen IS, Lin SM, Chuang WL, Liaw YF.

Aliment Pharmacol Ther. 2007 May 1;25(9):1029-37.

8.

Clinical outcome of chronic hepatitis C in patients treated with interferon: comparison between responders and non-responders.

Morisco F, Marmo R, Iasevoli P, Sessa G, Tuccillo C, Del Vecchio Blanco C, Caporaso N.

Ital J Gastroenterol Hepatol. 1999 Aug-Sep;31(6):454-8.

PMID:
10575561
9.
10.

Natural course of asymptomatic hepatitis C virus-infected patients and hepatocellular carcinoma after interferon therapy.

Okanoue T, Minami M, Makiyama A, Sumida Y, Yasui K, Itoh Y.

Clin Gastroenterol Hepatol. 2005 Oct;3(10 Suppl 2):S89-91.

PMID:
16234069
11.

Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.

Cacoub P, Lidove O, Maisonobe T, Duhaut P, Thibault V, Ghillani P, Myers RP, Leger JM, Servan J, Piette JC.

Arthritis Rheum. 2002 Dec;46(12):3317-26.

12.

Long-term liver histology improvement in patients with chronic hepatitis C and sustained response to interferon.

Toccaceli F, Laghi V, Capurso L, Koch M, Sereno S, Scuderi M; Italian Hepanet Group.

J Viral Hepat. 2003 Mar;10(2):126-33.

PMID:
12614469
13.

Treatment of chronic hepatitis C with interferon-alpha. Clinical histological and virological implications.

Olaso V, Córdoba J, Berenguer M, Prieto M, Lainez B, Argüello L, Valverde J, Pascual S, Gobernado M, Berenguer J.

Rev Esp Enferm Dig. 1997 Jul;89(7):531-50. English, Spanish.

PMID:
9265839
14.

Interferon therapy in HCV-positive mixed cryoglobulinaemia: viral and host factors contributing to efficacy of the therapy.

Mazzaro C, Carniello GS, Colle R, Doretto P, Mazzi G, Crovatto M, Santini GF, Tulissi P, Gregoretti M, Mazzoran L, Russo A, Silvestri F, Pozzato G.

Ital J Gastroenterol Hepatol. 1997 Aug;29(4):343-50.

PMID:
9476189
15.

Clinical significance of hepatic HCV RNA in patients with chronic hepatitis C demonstrating long-term sustained response to interferon-alpha therapy.

Larghi A, Tagger A, Crosignani A, Ribero ML, Bruno S, Portera G, Battezzati PM, Maggioni M, Fasola M, Zuin M, Podda M.

J Med Virol. 1998 May;55(1):7-11.

PMID:
9580879
16.

Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death.

Kasahara A, Tanaka H, Okanoue T, Imai Y, Tsubouchi H, Yoshioka K, Kawata S, Tanaka E, Hino K, Hayashi K, Tamura S, Itoh Y, Kiyosawa K, Kakumu S, Okita K, Hayashi N.

J Viral Hepat. 2004 Mar;11(2):148-56.

PMID:
14996350
17.

Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis.

Gramenzi A, Andreone P, Fiorino S, Cammà C, Giunta M, Magalotti D, Cursaro C, Calabrese C, Arienti V, Rossi C, Di Febo G, Zoli M, Craxì A, Gasbarrini G, Bernardi M.

Gut. 2001 Jun;48(6):843-8.

18.

Long-term histological prognosis and serum fibrosis markers in chronic hepatitis C patients treated with interferon.

Kojima H, Hongo Y, Harada H, Inoue T, Miyaji K, Kashiwagi M, Momose T, Arisaka Y, Fukui H, Murai S, Tokita H, Kamitsukasa H, Yagura M, Katsu K.

J Gastroenterol Hepatol. 2001 Sep;16(9):1015-21.

PMID:
11595066
19.

The impact of antiviral therapy on the course of chronic HCV infection. A systematic review.

Almasio PL, Venezia G, Craxì A.

Panminerva Med. 2003 Sep;45(3):175-82. Review.

PMID:
14618115
20.

Long-term follow-up of sustained responders to interferon therapy, in patients with chronic hepatitis C.

Toyoda H, Kumada T, Tokuda A, Horiguchi Y, Nakano H, Honda T, Nakano S, Hayashi K, Katano Y, Nakano I, Hayakawa T, Nishimura D, Kato K, Imada K, Imoto M, Fukuda Y; Yon-Ken HCV-HCC Follow-up Study Group.

J Viral Hepat. 2000 Nov;7(6):414-9.

PMID:
11115052

Supplemental Content

Support Center